Chrysavgi Elissavet L.
- Country
- Greece
- Department
- Hematology Clinic
Research Overview
- Phase III Multicenter Study on Safety, Pharmacokinetics, and Efficacy of Crovalimab vs. Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients on Complement Inhibitors
- Evaluation of Bortezomib and Daratumumab-Based Regimens in Primary Plasma Cell Leukemia: A Phase II Multicenter Study
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bleximenib, Venetoclax, and Azacitidine in Acute Myeloid Leukemia with KMT2A Rearrangements or NPM1 Mutations
Data & Insights
Has run more than one trial at 16 of 125 partner sites.
Specializations
Hematologic Disorders
This investigator specializes in treating paroxysmal nocturnal hemoglobinuria (PNH), exploring various therapeutic approaches including complement inhibitor treatments and combination therapies.
- Novel combination therapies for PNH
- Long-term disease management strategies
- Complement inhibitor treatments
The research extends to evaluating treatment outcomes in both treatment-naive and previously treated PNH patients.
Blood Cancers
The investigator conducts research in primary plasma cell leukemia, focusing on innovative treatment combinations and maintenance therapies.
- First-line treatment protocols
- Bortezomib-based combination regimens
- Maintenance therapy approaches
The work encompasses frontline treatment strategies for plasma cell disorders.
Transplant Complications
Research interests include hematopoietic stem cell transplant-associated thrombotic microangiopathy and its treatment approaches.
- Post-transplant complications
- Novel therapeutic interventions
- Treatment of transplant-related TMA
The focus includes investigating targeted therapies for transplant-associated complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.